---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-011892"
form_type: "8-K/A"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2023-04-12T23:59:59+00:00"
generated_at: "2026-06-17T03:06:33.861308+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Evofem Biosciences issues $769K convertible notes and warrants for ~$490K net

## Summary
- Aggregate $769,230.76 in senior subordinate convertible notes issued to investors.
- Warrants to purchase 76,923,077 shares of common stock issued.
- Investors paid $650 per $1,000 principal amount (~35% discount).
- Net proceeds to company after expenses approximately $490,000.
- Offering closed April 5, 2023; this 8-K/A corrects a typo in the original report.

## SEC filing metadata
- accession: 0001493152-23-011892
- form_type: 8-K/A
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2023-04-12T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315223011892/0001493152-23-011892-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315223011892/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-011892
- JSON: https://secwatch.observer/filing/0001493152-23-011892.json
- Plain text: https://secwatch.observer/filing/0001493152-23-011892.txt

## Key facts
- Material Agreements
  Evofem Biosciences, Inc. entered into Securities Purchase Agreement with certain investors valued at $769,230.76 (effective 2023-04-05).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: certain investors
  - Value: $769,230.76
  - Effective: 2023-04-05
  source text: On April 5, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company ”) entered into a securities purchase agreement (“ SPA ”), with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $769,230.76
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000149315223011892/0001493152-23-011892-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.